Everolimus in every day practice of metastatic renal cell carcinoma therapy – one center experience
Journal Title: OncoReview - Year 2016, Vol 6, Issue 3
Abstract
Introduction: Everolimus is a selective mTOR inhibitor which received approval for treatment of advanced renal cell carcinoma (mRCC) after progression on or after treatment with VEGF-targeted therapy. The aim of this study was to evaluate the efficiency and toxicity profile of everolimus in second line therapy of mRCC. The authors also assessed the impact of clinicopathological factors on the effectiveness of everolimus.Methods: The retrospective analysis was conducted on the medical records of 33 mRCC patients who were treated with everolimus in second line therapy after progression on interferon or tyrosine kinase inhibitors (sunitinib or pazopanib) during the years 2010–2016.Results: Median time of treatment with everolimus was 4 months (range from 1 to 58 months). Median progression free survival was 4 months and overall survival (OS) was 11 months. The best response (PR + CR + SD) was reported in 57% of patients. Toxicity in grade 3–4 was reported in 9 (27%) of patients. Clinicopathological factors associated with progression during everolimus therapy were: smoking and alcohol abuse (p = 0.029), higher Furman grade (p = 0.166), tumor necrosis (p = 0.383), fat tissue infiltration (p = 0.040), lymph node (p = 0.193) and adrenal metastases (p = 0.067). Factors which increase the risk of everolimus toxicity were worse performance status (p = 0.333) and more advanced disease at the beginning (lymph nodes metastases, p = 0.05) and higher Furman grade (p = 0.04).Conclusions: Cigarettes use and/or alcohol abuse, adrenal metastases, fat tissue had significantly negative influence on survival. Grade 3–4 toxicity were reported more frequently in patients with worse performance status and more advanced disease at the time of diagnosis.
Authors and Affiliations
Joanna Huszno, Elżbieta Nowara
Keywords
Related Articles
- EP ID EP80369
- DOI -
- Views 212
- Downloads 0
Merkel cell carcinoma
Merkel cell carcinoma (MCC) is a rare cutaneous malignancy, with aggressive behaviour. The discovery of MCC polyomavirus (MCPyV) provided a major insight into pathogenesis of MCC, as MCPyV is present in most MCC tumours....
The role of histopathological examination, therapeutic difficulties and thromboembolism treatment during palliative chemotherapy in patient with antithrombin deficiency , colon cancer and endometrial cancer
Palliative chemotherapy in patients with thrombophilia is a challenge for clinical oncologists. On one hand the optimal treatment should be very safe for patient, on the other hand – as effective as possible. That therap...
Cardiotoxicity of radiotherapy in breast cancer patients
Zaburzenia psychiczne u chorych na nowotwory - podejście kliniczne
Pacjent z chorobą nowotworową nie tylko mierzy się z chorobą pierwotną, ale także narażony jest na stany emocjonalne, które przy niesprzyjających warunkach i dużym obciążeniu mogą prowadzić do depresji, zwiększonego lęku...
Idiopathic venous thromboembolism or occult cancer?
The relationship between cancer and an increased incidence of venous thromboembolism (VTE) is well documented. VTE is a common complication of cancer, which usually occurs in the advanced stages of the disease. It often...